Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 6, 2008, Pages 914-921

  Wong, Vincent Wai Sun ^b   Wong, Grace Lai Hung ^b   Tsang, Steven Woon Choi ^c   Hui, Alex Yui ^b   Chan, Anthony Wing Hong ^b   Choi, Paul Cheung Lung ^b   So, Wing Yee ^b   Tse, Ada Mei Ling ^b   Chan, Francis Ka Leung ^b   Sung, Joseph Jao Yiu ^b   Chan, Henry Lik Yuen ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c TSEUNG KWAN O HOSPITAL   (Hong Kong)

Author keywords

Adiponectin; Diabetes mellitus; Fatty liver; Metabolic syndrome X; Tumor necrosis factor alpha

Indexed keywords

ADIPONECTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

EID: 44949172829     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05344.x     Document Type: Article

References (45)

1. Nomura H, Kashiwagi S, Hayashi J et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn. J. Med. 1988 27: 142 9.
2. Bellentani S, Saccoccio G, Masatti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000 132: 112 17.
3. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004 40: 1387 95.
4. Jimba S, Nakagami T, Takahashi M et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 2005 22: 1141 5.
5. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population: examination of 503 consecutive fatal traffic casualities. Scand. J. Gastroenterol. 1977 12: 593 9.
6. Adams LA, Lymp JF, St. Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005 129: 113 21.
7. Wong VW, Chan HL, Hui AY et al. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment. Pharmacol. Ther. 2004 20: 45 9.
8. Hui AY, Wong VW, Chan HL et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment. Pharmacol. Ther. 2005 21: 407 13.
9. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am. J. Gastroenterol. 2003 98: 2042 7.
10. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990 11: 74 80.
11. Wong VW, Hui AY, Tsang SW et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006 24: 1215 22.
12. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003 37: 917 23.
13. Wong VW, Hui AY, Tsang SW et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006 4: 1154 61.
14. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH. TNF-alpha or adiponectin? Hepatology 2004 40: 46 54.
15. Bugianesi E, Pagotto U, Manini R et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab. 2005 90: 3498 504.
16. Pagano C, Soardo G, Esposito W et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur. J. Endocrinol. 2005 152: 113 18.
17. Aygun C, Senturk O, Hulagu S et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2006 18: 175 80.
18. Louthan MV, Barve S, McClain CJ, Joshi-Barve S. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J. Pediatr. 2005 147: 835 8.
19. Zou CC, Liang L, Hong F, Fu JF, Zhao ZY. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr. J. 2005 52: 519 24.
20. Musso G, Gambino R, Biroli G et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2005 100: 2438 46.
21. Sargin H, Sargin M, Gozu H et al. Is adiponectin level a predictor of nonalcoholic fatty liver disease in nondiabetic male patients? World J. Gastroenterol. 2005 11: 5874 7.
22. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001 34: 1158 63.
23. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003 37: 343 50.
24. Ko GT, Tang J, Chan JC et al. Lower BMI cut-off value to define obesity in Hong Kong Chinese: an analysis based on body fat assessment by bioelectrical impedance. Br. J. Nutr. 2001 85: 239 42.
25. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006 29 (Suppl. 1 S43 8.
26. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005 366: 1059 62.
27. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999 94: 2467 74.
28. El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000 404: 398 402.
29. Chan HL, Tse AM, Chim AM et al. Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. J. Gastroenterol. Hepatol. 2008 23: 783 9.
30. Woo JG, Dolan LM, Deka R et al. Interactions between noncontiguous haplotypes in the adiponectin gene ACDC are associated with plasma adiponectin. Diabetes 2006 55: 523 9.
31. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 2004 323: 630 5.
32. Jang Y, Lee JH, Chae JS et al. Association of the 276G->T polymorphism of the adiponectin gene with cardiovascular disease risk factors in nondiabetic Koreans. Am. J. Clin. Nutr. 2005 82: 760 7.
33. Mackevics V, Heid IM, Wagner SA et al. The adiponectin gene is associated with adiponectin levels but not with characteristics of the insulin resistance syndrome in healthy Caucasians. Eur. J. Hum. Genet. 2006 14: 349 56.
34. Menzaghi C, Ercolino T, Di Paola R et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002 51: 2306 12.
35. Filippi E, Sentinelli F, Romeo S et al. The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery disease patients (age < or = 50 years). J. Mol. Med. 2005 83: 711 19.
36. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004 99: 2365 8.
37. Satapathy SK, Garg S, Chauhan R et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004 99: 1946 52.
38. Memon RA, Grunfeld C, Feingold KR. TNF-alpha is not the cause of fatty liver disease in obese diabetic mice. Nat. Med. 2001 7: 2 3.
39. Deng QG, She H, Cheng JH et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005 42: 905 14.
40. Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005 129: 1663 74.
41. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 2007 46: 1104 10.
42. Higuchi T, Seki N, Kamizono S et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998 51: 605 12.
43. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor á promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002 122: 274 80.
44. Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005 143: 722 8.
45. Chan HL, de Silva HJ, Leung NW et al. How should we manage patients with non-alcoholic fatty liver disease in 2007? J. Gastroenterol. Hepatol. 2007 22: 801 8.